Abbott Laboratories (ABT) Target Raised to $143 with 35% Upside
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowAbbott Laboratories (ABT) trades at $105.70 with a P/E ratio of 19x forward earnings. Barclays analyst Matt Miksic has set a target price of $143, indicating a potential upside of 35%. Following the acquisition of Exact Sciences for $21 billion, Abbott raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60. Despite year-to-date declines of 16% and a revenue of $12.59 billion, analysts expect accelerating sales and earnings growth in H2 2026, positioning the company as a potential recovery play for investors.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Abbott Laboratories (ABT)
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABT news
- Abbott Laboratories (ABT) Faces Class-Action Lawsuit Over PediaSure
- Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
- Adeptus Biotechnologies Stock Rating Maintained by BTIG
- Abbott Laboratories (ABT) Director Daniel Starks Buys $926,537 in Shares
- Abbott Labs (ABT) stock price target cut to $120 by Benchmark
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
S&P 500 and Nasdaq Rise as AI Stocks Rebound Before Earnings
Oct 19
A&W (TSX:AW) Q3 Results Show Margin Squeeze Impact
Oct 18